版本:
中国

BRIEF-Pfizer and Lilly receive FDA fast track designation for Tanezumab

June 13 Pfizer Inc:

* Pfizer and Lilly receive FDA fast track designation for Tanezumab

* ‍phase 3 global clinical development program for Tanezumab is currently ongoing​

* ‍Results are projected to begin reporting out in 2018​ Source text for Eikon: Further company coverage: and

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐